Parkside Financial Bank & Trust Buys 834 Shares of Johnson & Johnson $JNJ

Parkside Financial Bank & Trust grew its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% in the second quarter, HoldingsChannel.com reports. The fund owned 18,965 shares of the company’s stock after acquiring an additional 834 shares during the period. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,897,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $48,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson in the first quarter valued at $65,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. UBS Group upped their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $186.50 on Friday. The stock’s fifty day simple moving average is $184.25 and its 200 day simple moving average is $168.63. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $449.34 billion, a P/E ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.